DexCom/$DXCM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Ticker
$DXCM
Sector
Primary listing
Employees
10,250
Headquarters
Website
DexCom Metrics
BasicAdvanced
$29B
40.83
$1.80
1.52
-
Price and volume
Market cap
$29B
Beta
1.52
52-week high
$93.25
52-week low
$54.11
Average daily volume
5.3M
Financial strength
Current ratio
1.565
Quick ratio
1.346
Long term debt to equity
49.342
Total debt to equity
92.476
Interest coverage (TTM)
22.61%
Profitability
EBITDA (TTM)
992.8
Gross margin (TTM)
59.01%
Net profit margin (TTM)
15.96%
Operating margin (TTM)
17.22%
Effective tax rate (TTM)
24.85%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
7.02%
Return on equity (TTM)
30.63%
Valuation
Price to earnings (TTM)
40.829
Price to revenue (TTM)
6.355
Price to book
10.49
Price to tangible book (TTM)
10.91
Price to free cash flow (TTM)
27.026
Free cash flow yield (TTM)
3.70%
Free cash flow per share (TTM)
2.714
Growth
Revenue change (TTM)
14.21%
Earnings per share change (TTM)
7.76%
3-year revenue growth (CAGR)
17.37%
10-year revenue growth (CAGR)
28.94%
3-year earnings per share growth (CAGR)
44.54%
10-year earnings per share growth (CAGR)
25.60%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire·2 weeks ago
Watch CNBC's exclusive interview with Dexcom CEO Jake Leach
CNBC Television·2 weeks ago
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $29B as of January 29, 2026.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 40.83 as of January 29, 2026.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of January 29, 2026.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.